

Supplementary

Table S1 Grade 3 or higher treatment-emergent adverse events in the Asian subgroup considered treatment-related by the investigator (Safety population)

	Amivantamab-chemotherapy N=62				Chemotherapy N=116		
System organ class Preferred term	Related to Any	Related to amivantamab	Related to carboplatin	Related to pemetrexed	Related to any	Related to carboplatin	Related to pemetrexed
Participants with 1 or more related AEs	45 (72.6%)	28 (45.2%)	36 (58.1%)	39 (62.9%)	40 (34.5%)	39 (33.6%)	38 (32.8%)
Blood and lymphatic system disorders	37 (59.7%)	6 (9.7%)	32 (51.6%)	36 (58.1%)	33 (28.4%)	32 (27.6%)	31 (26.7%)
Neutropenia	28 (45.2%)	5 (8.1%)	28 (45.2%)	26 (41.9%)	23 (19.8%)	21 (18.1%)	22 (19.0%)
Leukopenia	17 (27.4%)	2 (3.2%)	15 (24.2%)	16 (25.8%)	13 (11.2%)	12 (10.3%)	13 (11.2%)
Anaemia	10 (16.1%)	0	8 (12.9%)	10 (16.1%)	12 (10.3%)	11 (9.5%)	11 (9.5%)
Thrombocytopenia	13 (21.0%)	4 (6.5%)	13 (21.0%)	12 (19.4%)	9 (7.8%)	8 (6.9%)	8 (6.9%)
Febrile neutropenia	2 (3.2%)	0	1 (1.6%)	2 (3.2%)	3 (2.6%)	1 (0.9%)	3 (2.6%)
Pancytopenia	0	0	0	0	1 (0.9%)	1 (0.9%)	1 (0.9%)
Coagulopathy	0	0	0	0	0	0	0
Lymphopenia	3 (4.8%)	0	2 (3.2%)	3 (4.8%)	0	0	0
Myelosuppression	2 (3.2%)	0	2 (3.2%)	2 (3.2%)	0	0	0
Investigations	3 (4.8%)	3 (4.8%)	0	2 (3.2%)	5 (4.3%)	5 (4.3%)	5 (4.3%)
Alanine aminotransferase increased	2 (3.2%)	2 (3.2%)	0	1 (1.6%)	5 (4.3%)	5 (4.3%)	5 (4.3%)
Gamma-glutamyltransferase increased	0	0	0	0	1 (0.9%)	1 (0.9%)	1 (0.9%)
Blood creatinine increased	1 (1.6%)	1 (1.6%)	0	1 (1.6%)	0	0	0
Metabolism and nutrition	5 (8.1%)	3 (4.8%)	4 (6.5%)	4 (6.5%)	3 (2.6%)	3 (2.6%)	2 (1.7%)

disorders							
Decreased appetite	0	0	0	0	2 (1.7%)	2 (1.7%)	2 (1.7%)
Hyponatraemia	4 (6.5%)	2 (3.2%)	4 (6.5%)	4 (6.5%)	1 (0.9%)	1 (0.9%)	0
Hypoalbuminaemia	1 (1.6%)	1 (1.6%)	0	0	0	0	0
Nervous system disorders	1 (1.6%)	0	1 (1.6%)	0	2 (1.7%)	2 (1.7%)	2 (1.7%)
Headache	0	0	0	0	1 (0.9%)	1 (0.9%)	1 (0.9%)
Seizure	0	0	0	0	1 (0.9%)	1 (0.9%)	1 (0.9%)
Optic neuritis	1 (1.6%)	0	1 (1.6%)	0	0	0	0
Vascular disorders	0	0	0	0	2 (1.7%)	2 (1.7%)	2 (1.7%)
Deep vein thrombosis	0	0	0	0	1 (0.9%)	1 (0.9%)	1 (0.9%)
Embolism	0	0	0	0	1 (0.9%)	1 (0.9%)	1 (0.9%)
Endocrine disorders	0	0	0	0	1 (0.9%)	1 (0.9%)	0
Inappropriate antidiuretic hormone secretion	0	0	0	0	1 (0.9%)	1 (0.9%)	0
Gastrointestinal disorders	5 (8.1%)	3 (4.8%)	5 (8.1%)	5 (8.1%)	1 (0.9%)	1 (0.9%)	1 (0.9%)
Diarrhoea	0	0	0	0	1 (0.9%)	1 (0.9%)	1 (0.9%)
Nausea	1 (1.6%)	0	1 (1.6%)	1 (1.6%)	1 (0.9%)	1 (0.9%)	0
Glossitis	1 (1.6%)	1 (1.6%)	1 (1.6%)	1 (1.6%)	0	0	0
Mouth haemorrhage	0	0	0	0	0	0	0
Mouth ulceration	1 (1.6%)	1 (1.6%)	1 (1.6%)	1 (1.6%)	0	0	0
Periodontal disease	0	0	0	0	0	0	0
Stomatitis	1 (1.6%)	0	1 (1.6%)	1 (1.6%)	0	0	0
Upper gastrointestinal haemorrhage	1 (1.6%)	1 (1.6%)	1 (1.6%)	1 (1.6%)	0	0	0
General disorders and administration site conditions	8 (12.9%)	6 (9.7%)	6 (9.7%)	8 (12.9%)	1 (0.9%)	1 (0.9%)	1 (0.9%)
Fatigue	3 (4.8%)	1 (1.6%)	3 (4.8%)	3 (4.8%)	1 (0.9%)	1 (0.9%)	1 (0.9%)
Asthenia	1 (1.6%)	1 (1.6%)	1 (1.6%)	1 (1.6%)	0	0	0
Malaise	3 (4.8%)	3 (4.8%)	2 (3.2%)	3 (4.8%)	0	0	0
Mucosal inflammation	1 (1.6%)	1 (1.6%)	1 (1.6%)	1 (1.6%)	0	0	0
Oedema peripheral	2 (3.2%)	1 (1.6%)	0	2 (3.2%)	0	0	0
Hepatobiliary disorders	0	0	0	0	1 (0.9%)	0	1 (0.9%)

Hepatic function abnormal	0	0	0	0	1 (0.9%)	0	1 (0.9%)
Respiratory, thoracic and mediastinal disorders	4 (6.5%)	2 (3.2%)	2 (3.2%)	3 (4.8%)	1 (0.9%)	1 (0.9%)	1 (0.9%)
Pulmonary artery thrombosis	0	0	0	0	1 (0.9%)	1 (0.9%)	1 (0.9%)
Dyspnoea exertional	1 (1.6%)	0	0	1 (1.6%)	0	0	0
Epistaxis	0	0	0	0	0	0	0
Interstitial lung disease	1 (1.6%)	1 (1.6%)	0	0	0	0	0
Pneumothorax	1 (1.6%)	0	1 (1.6%)	1 (1.6%)	0	0	0
Pulmonary embolism	1 (1.6%)	1 (1.6%)	1 (1.6%)	1 (1.6%)	0	0	0
Cardiac disorders	1 (1.6%)	1 (1.6%)	0	1 (1.6%)	0	0	0
Ventricular fibrillation	1 (1.6%)	1 (1.6%)	0	1 (1.6%)	0	0	0
Infections and infestations	9 (14.5%)	5 (8.1%)	4 (6.5%)	4 (6.5%)	0	0	0
Herpes virus infection	2 (3.2%)	1 (1.6%)	1 (1.6%)	1 (1.6%)	0	0	0
Paronychia	2 (3.2%)	2 (3.2%)	0	0	0	0	0
Sepsis	2 (3.2%)	0	2 (3.2%)	2 (3.2%)	0	0	0
Soft tissue infection	1 (1.6%)	1 (1.6%)	0	0	0	0	0
Staphylococcal infection	1 (1.6%)	1 (1.6%)	0	0	0	0	0
Urinary tract infection	1 (1.6%)	0	1 (1.6%)	1 (1.6%)	0	0	0
Injury, poisoning and procedural complications	3 (4.8%)	3 (4.8%)	0	0	0	0	0
Infusion related reaction	3 (4.8%)	3 (4.8%)	0	0	0	0	0
Skin and subcutaneous tissue disorders	8 (12.9%)	7 (11.3%)	0	2 (3.2%)	0	0	0
Dermatitis acneiform	5 (8.1%)	5 (8.1%)	0	1 (1.6%)	0	0	0
Onycholysis	0	0	0	0	0	0	0
Palmar-plantar erythrodysesthesia syndrome	1 (1.6%)	1 (1.6%)	0	0	0	0	0
Rash	2 (3.2%)	1 (1.6%)	0	1 (1.6%)	0	0	0

An AE is categorized as related if assessed by the investigator as possibly, probably, or very likely related to study agent. Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event. Adverse events are coded

using MedDRA Version 25.0.

Table S2 Treatment-emergent serious adverse events (TESAEs) reported by at least two participants in either group the Asian subgroup (Safety population)

System organ class Preferred term	Amivantamab-chemotherapy N=62	Chemotherapy N=116
Participants with 1 or more TESAE	25 (40.3%)	20 (17.2%)
Blood and lymphatic system disorders	7 (11.3%)	6 (5.2%)
Febrile neutropenia	2 (3.2%)	2 (1.7%)
Thrombocytopenia	3 (4.8%)	1 (0.9%)
Anaemia	2 (3.2%)	1 (0.9%)
Myelosuppression	2 (3.2%)	0
Infections and infestations	8 (12.9%)	3 (2.6%)
COVID-19	2 (3.2%)	0
Sepsis	2 (3.2%)	0
Respiratory, thoracic and mediastinal disorders	6 (9.7%)	1 (0.9%)
Dyspnoea	4 (6.5%)	0
Cardiac disorders	3 (4.8%)	1 (0.9%)
Supraventricular tachycardia	2 (3.2%)	0